Haystack MRD® by Quest Diagnostics is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after cancer treatment. Based on more than 20 years of clinical development and technology from pioneers in cancer genomics at Johns Hopkins University, Haystack MRD's purpose-built, high-precision science delivers novel insights that can help inform treatment decision-making.
| Website | http://www.haystackmrd.com |
| Revenue | $120 million |
| Employees | 60 (46 on RocketReach) |
| Founded | 2021 |
| Address | 301 W 29th St Suite 2004U, Baltimore, Maryland 21211, US |
| Industry | Biotechnology Research |
| Competitors | Tempus Labs, Inc., Exact Sciences, Guardant Health, GRAIL, Foundation Medicine, NeoGenomics Laboratories, LifeLabs Medical Laboratory Services, PathAI, Biocept, Inc., carisls +44 more (view full list) |
Looking for a particular Haystack Oncology employee's phone or email?
Haystack Oncology Questions
The Haystack Oncology annual revenue was $120 million in 2026.
Frank Holtrup is the Chief Technology Officer, Managing Director Haystack Oncology GmbH of Haystack Oncology.
46 people are employed at Haystack Oncology.
Haystack Oncology is based in Baltimore, Maryland.
Top Haystack Oncology Employees
-
13
-
23
-
11
-
Erika Kerr
Executive Sales Director at Haystack Oncology
Philadelphia, PA, US12 -
1 -
21
-
Hannah Quinn
Director of Laboratory Operations at Haystack Oncology
Severna Park, MD, US13 -
Tweed Hanusek
Sr. Director of Quality Assurance at Haystack Oncology
Chapel Hill, NC, US13
Related Companies
